Iteos Therapeutics Inc Up 6.62% To $11.75 After Earnings Beat

Iteos Therapeutics Inc (ITOS) said before open Wednesday that it lost $0.85 per share in quarter four 2023. The company reported $0.00 in revenue

In the same quarter a year ago, the company earned $0.54 per share on revenue of $53.9 thousand.

The stock is up 6.62% to $11.75 after the report.

Iteos Therapeutics Inc's profit margins took a hit as earnings fell at a faster pace than revenues.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Iteos Therapeutics Inc has performed a little below average during the past few months. Before the report, Iteos Therapeutics Inc received a Long-Term Technical Rank by InvestorsObserver of 36, putting it in the bottom half of stocks. The firm set a 52-week low on October 12, 2023 at $8.2 and set a 52-week high on May 26, 2023 at $18.24.

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.